Acetylcholine (ACh) is a phylogenetically ancient molecule involved in cell-to-cell signaling in almost all life-forms on earth. Cholinergic components, including ACh, choline acetyltransferase, acetylcholinesterase, and muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively) have been identified in numerous non-neuronal cells and tissues, including keratinocytes, cancer cells, immune cells, urinary bladder, airway epithelial cells, vascular endothelial cells, and reproductive organs, among many others. Stimulation of the mAChRs and nAChRs elicits cell-specific functional and biochemical effects. These findings support the notion that non-neuronal cholinergic systems are expressed in certain cells and tissues and are involved in the regulation of their function and that cholinergic dysfunction is related to the pathophysiology of certain diseases. They also provide clues for development of drugs with novel mechanisms of action.
Introduction
Much progress has been made in our understanding of non-neuronal cholinergic systems since the first symposium on "The Non-neuronal Cholinergic System" was held at the 73rd Annual Meeting of The Japanese Pharmacological Society (March 24, 2000; Yokohama) (1) . In the interim, there has been worldwide recognition of the biological significance of non-neuronal cholinergic systems, and the First and the Second International Symposiums on Non-neuronal Acetylcholine were held in San Francisco, CA, USA (2002) and Mainz, Germany (2006) , respectively (2, 3) . Furthermore, the renowned pharmacology text book "Goodman and Gilman's The Pharmacological Basis of Therapeutics (11th ed, 2006)" now has a new section entitled "Extraneuronal Cholinergic Systems (page 153)," which introduces the idea that acetylcholine (ACh) is present in the vast majority of human cells, including epithelial, mesothelial, and endothelial cells (ECs); circulating cells; and immune cells. With all of that as background, we organized a symposium on the "Basic and Clinical Aspects of Non-neuronal ACh" for the occasion of the 80th Annual Meeting of The Japanese Pharmacological Society (March 15, 2007, Nagoya) . The aim of this review is to provide additional insight into the nature of non-neuronal cholinergic systems and their biological and clinical significance.
Cholinergic components

2-1. ACh and its synthesizing enzymes
Almost all the life-forms on the earth appear to have the ability to synthesize acetylcholine (ACh). We have detected ACh and ACh-synthesizing activity in bacteria, archaea, and eucarya (4 -6) ; and it is evident that ACh is a phylogenetically ancient substance that evolved well before the advent of animals with a nervous system (7, 8) . Nonetheless, most currently available information on ACh was derived from research on the nervous systems of mammalian species, where ACh is synthesized mainly by choline acetyltransferase (ChAT) from choline and acetyl coenzyme A (AcCoA), although in the periphery, the mitochondrial enzyme carnitine acetyltransferase (CarAT) also participates in ACh synthesis (9) . This is noteworthy, as the activities of ACh-synthesizing enzymes determined using the radiometric method of Fonnum (10) with [ 3 H]choline do not always correlate well with the observed ACh synthesis in tissues. This can be ascribed, at least in part, to the fact that both ChAT and CarAT are involved in ACh synthesis in the periphery. We found that in lymphocytes the ACh content correlates rather well with ChAT activity but not with either CarAT activity or total ACh synthesis (11) . Furthermore, immunological stimulation of lymphocytes selectively stimulates ChAT activity without affecting CarAT activity. This suggests that in lymphocyte ACh is mainly synthesized by ChAT and that CarAT plays only a minor role in ACh synthesis. It is therefore highly advisable to determine both ChAT and CarAT activities using selective inhibitors for the respective enzymes, such as bromoACh (BrACh) and bromoacetylcarnitine (BrACar) (9) .
The ACh-synthesizing activity found in bacteria, archaea, fungi, higher plants, and invertebrate animals can show resistance to or varying degrees of susceptibility to BrACh and BrACar (4, 5) . Most samples containing relatively high levels of ACh, such as Shiitake mushroom, bamboo shoot, squid, and neresis show ACh-synthesizing activities that were highly sensitive to BrACh, which suggests that a ChAT-like enzyme is responsible for ACh synthesis in samples where substantial amounts of ACh are actively synthesized. However, further studies will be necessary to fully characterize the enzymes involved in ACh synthesis in these organisms.
2-2. ACh receptors
Expression of both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively) has been detected in numerous non-neuronal cells and organs (3) . Most express all five mAChR subtypes (M 1 -M 5 ), although the level of expression of each subtype may vary. In addition, a number of neuron type nAChR subunits (α2, α3, α4, α5, α6, α7, α9, α10, β2, β3, and β4) have been identified in non-neuronal cells and organs, but no muscle type subunits (α1, β1, γ, and δ) have been detected.
2-3. Acetylcholinesterase and butyrylcholinesterase
At the neuromuscular junction, ACh released from nerve endings is cleared within several milliseconds by the action of acetylcholinesterase (AChE), which cleaves ACh into choline and acetic acid. Expression of both AChE and butyrylcholinesterase (BuChE) has been detected in most non-neuronal cells and organs (3); however, the precise roles they play in the regulation of non-neuronal cholinergic activity remain unclear.
2-4. Vesicular ACh transporter
In cholinergic neurons, ACh is transported into the synaptic vesicles via the vesicular ACh transporter (VAChT) and stored there until released by exocytosis. Expression of VAChT has been detected in bronchial epithelium (12) , but skin (13), urothelium (14) , and T cells (7) do not appear to express VAChT. Instead, ACh appears to be synthesized and released when necessary, without storage. On the other hand, two polyspecific organic cation transporter subtypes, OCT1 and OCT3, are reportedly involved in the release of ACh in the human placenta (15) and in murine bronchial epithelium (16).
2-5. High affinity choline transporter
In cholinergic neurons, choline taken up via the high affinity choline transporter (CHT1) is utilized exclusively for ACh synthesis. OCT1, OCT2, and OCT3 also have the ability to transport choline from the extracellular space into some cells. CHT1 is expressed in airway epithelial cells (17) and T cells (18) , while OCT1, OCT2, and OCT3 are expressed in airway epithelial cells (19) and placenta (15) .
Although detailed information about the source of choline for ACh synthesis in non-neuronal cells and organs is not yet available, choline taken up via either CHT1 or OCTs is certainly one of candidate substrates for ACh synthesis.
Non-neuronal cholinergic systems expressed in mammalian species
In this review, we will briefly discuss the nonneuronal cholinergic systems expressed in the following cells and organs:
-Keratinocytes -Cancer cells -Immune cells -Urinary bladder -Airway epithelial cells -Vascular endothelial cells -Reproductive organs -Miscellaneous
3-1. Keratinocytes
The non-neuronal cholinergic system in human skin was extensively reviewed recently by Kurzen et al. (20) . In addition, the biological and clinical significance of epithelial nAChRs is discussed later in this issue (21) . ACh synthesis in keratinocytes is catalyzed by ChAT, while its degradation is catalyzed by AChE (20, 22, 23) . Epidermal and gingival keratinocytes express the M 1 -M 5 and M 2 -M 5 mAChR subtypes, respectively (24 -26) , as well as the α3, α5, α7, α9, and β2 nAChR subunits (3, 23) . ACh synthesized by and released from keratinocytes acts on both mAChRs and nAChRs in an autocrine and/ or paracrine fashion to modulate basic functions of the skin, including keratinocyte proliferation, differentiation, adhesion and migration, and epidermal barrier formation (20, 27) .
A novel endogenous ligand for the nAChR α7 subunit, secreted mammalian Ly-6/ urokinase plasminogen-type activator receptor-related protein (SLURP)-1, which is a member of the Ly-6/ uPAR protein superfamily isolated from human blood and urine, increases the incidence of apoptosis among cultured human keratinocytes (28, 29) . Conversely, SLURP-2, which shares substantial sequence homology with SLURP-1 and has been identified in human epidermal and oral keratinocytes, prevents keratinocyte apoptosis by acting on the α3 subunit (30, 31) . That both SLURP-1 and SLURP-2 appear to be expressed in a variety of cells and tissues (32) suggests study of their functions as endogenous nAChR ligands in non-neuronal cholinergic systems is warranted.
3-2. Cancer cells
Various cancer cells express both mAChRs and nAChRs and have the ability to synthesize ACh (33 -35).
3-2-1. Brest cancer cells
Two different murine mammary adenocarcinoma cell lines, LM2 and LM3, express functional mAChRs (36, 37) . Stimulation of these cell lines with carbachol increases their proliferation via M 2 and M 3 mAChRmediated pathways and facilitates angiogenesis via M 1 and M 2 mAChR-mediated pathways.
3-2-2. Small cell lung cancer cells
Human small cell lung cancer (SCLC) cells have the ability to produce ACh via ChAT and to express a number of mAChR and nAChR subtypes (38) . The roles of mAChRs in the regulation of SCLC cell proliferation are described in detail in this issue (39) .
Exposing SCLC cells to nicotine increases expression of α7 nAChRs and causes influx of Ca 2+ and activation of PKC, Raf-1, ERK1/ 2, and c-myc, which leads to increases in cell proliferation or inhibition of apoptosis (40) . Moreover, Schuller (40) has suggested the possibility that in addition to nicotine, its derivative nitrosamine NNK may interact with α7 nAChRs, leading to the development of lung cancer.
3-3. Immune cells
Although Pavlov and Tracey (41) proposed that there is neurological control over inflammatory cell function, lymphocytes, dendritic cells (DCs), and macrophages all clearly express cholinergic components sufficient to constitute their own cholinergic system (7, 42 -46) . A detailed description of the lymphocytic cholinergic system appears later in this issue (47) .
Lymphocytes, bone marrow-derived DCs, and peritoneal macrophages all express the five mAChR subtypes (M 1 -M 5 ) and several nAChR subunits (48) . Moreover, DCs express ChAT mRNA upon stimulation with lipopolisaccharide. These findings suggest that during immunological reactions, stimulated T cells and DCs have the ability to synthesize and release ACh, which in turn acts in an autocrine and/ or paracrine fashion on mAChRs and nAChRs on T cells, DCs, and macrophages to modulate immune function (48) .
3-4. Urinary bladder
The expression of a non-neuronal cholinergic system in urinary bladder is reviewed in this issue by Yoshida et al. (49) . Briefly, they observed strong ChAT-positive immunostaining in the urothelial and suburothelial regions of the human urinary bladder (50) . What is more, they also observed ACh release from urothelium that was facilitated by stretching the bladder. That this release of ACh was tetrodotoxin-insensitive indicates it to be of non-neuronal origin, which suggests that a nonneuronal cholinergic system contributes to the physiology and pathophysiology of human urinary bladder function.
Hanna-Mitchell et al. (14) found that rat urothelial cells express CHT1, ChAT, and CarAT. They also discovered expression of OCT3, which, as mentioned above, is thought to be involved in the release of ACh from non-neuronal cells, but they did not detect VAChT. RT-PCR analysis revealed that human urothelium expresses all five mAChR subtypes in the ranked order M 2 >>M 3 = M 5 >M 4 = M 1 (51) . Immunohistochemical analysis demonstrated differing patterns in the distribution of mAChR subtypes: M 1 is restricted to basal cells; M 2 is found almost exclusively in umbrella cells; M 3 and M 4 are homogenously distributed; and M 5 is distributed in decreasing gradient from luminal to basal cells. It may be that the apparent layer-specific distribution of mAChRs serves to stratify cholinergic regulation of urothelial function. Several nAChR α subunits are expressed in human urothelium in the ranked order α7>>α10>α9, as detected by real-time RT-PCR (51) . RT-PCR analysis also showed that mouse urothelium expresses the α2, α4, α5, α6, α7, α9, and α10 subunits, but not the α3 subunit (52).
3-5. Epithelial cells in the airways
Cholinergic components expressed by airway epithelial cells in humans, rats, and mice include ChAT, CHT1, VAChT, and OCT1, as well as various mAChR and nAChR subtypes, demonstrating the presence of a nonneuronal cholinergic system involved in the maintenance of cell-cell-contacts, stimulation of fluid-secretion, and regulation of ciliary beat frequency (8, 16) . Lips et al. (12) discovered that the pulmonary nonneuronal cholinergic system is down-regulated during acute allergic airway inflammation, suggesting a contribution to the epithelial shedding and ciliated cell dysfunction seen in such cases. In addition, Wessler et al. (53) investigated the activity of the cholinergic system in cystic fibrosis (CF) patients and found reduced levels of non-neuronal ACh. This could contribute to the deleterious changes in epithelial ion and water movements seen in CF, as ACh stimulates apical Cl − secretion and inhibits apical Na + and water absorption, thereby facilitating mucociliary clearance.
3-6. Reproductive organs
Reproductive organs express cholinergic system components and have the ability to synthesize ACh and express mAChRs or nAChRs.
3-6-1. Ovary cell
Under the control of follicle stimulating hormone (FSH), ACh is produced in granulosa cells (GCs) isolated from human antral follicles and likely also in their in vivo counterparts within the growing follicle (54) . mAChRs have been identified in GC membranes and cultured human GCs, where a number of mAChRmediated actions have been described, including regulation of proliferation and gap junctional communication. ACh may thus act as a local signaling factor within the GC compartment of growing antral follicles (55).
3-6-2. Amniotic membrane
Sakuragawa et al. (56) detected the presence of ChAT immunoreactivity in amniotic epithelial cells and the presence of ACh in the amniotic fluid. In addition, Horikoshi et al. (57) found that amniotic fluid collected after transient ligation of the uterine vessels near the lower and upper ends of the right horn of the pregnant rat contained higher levels of ACh than control samples, suggesting intrauterine hypoxia leads to increases in the level of ACh in amniotic fluid.
3-6-3. Placenta
ACh is expressed in the human placenta, where it acts via nAChR-mediated pathways to regulate nutrient transport, blood flow, and fluid volume in the placental vessels and vascularization during placental development (58) . Immunohistochemical analyses revealed the expression of the α2, α3, α4, α5, α7, α9, and α10 subunits in different combinations in rat cytotrophoblasts, human and rat syncytiotrophoblasts, Hofbauer cells, human amniotic epithelium, and rat visceral yolk sac epithelium (59) . In addition, Wessler et al. (60) showed that ACh is released via OCT1 and OCT3 in human placenta.
3-7. Vascular endothelial cells
It has long been known that vascular endothelial cells (ECs) express mAChRs and that their stimulation by agonists, including exogenously administered ACh, induces vascular smooth muscle relaxation, leading to a reduction in blood pressure mediated by the so called endothelium-derived relaxing factor, which was later revealed to be nitric oxide (NO). Given the absence of postsynaptic parasympathetic innervation of ECs and the presence of high levels of AChE and ChE activity in the blood, the origin of the ACh that should activate the mAChRs expressed by ECs had long been an enigma. However, by using a sensitive and specific radioimmunoassay to measure ACh levels in cultured bovine arterial ECs and primary cultured ECs from porcine cerebral microvessels, as well as in their conditioned media, Kawashima and his colleagues were able to demonstrate for the first time that ECs have the ability to synthesize and release ACh (61 -63) . In addition, they found phorbol myristate 13-acetate (PMA) significantly increased ACh synthesis in primary cultured ECs from porcine cerebral microvessels (63), suggesting a role for PKC in the regulation of ACh synthesis. Kirkpatrick et al. (64) discovered the presence of ChAT immunoreactivity and activity in ECs from human dermal blood vessels, monolayer cultures of human umbilical vein ECs, and in a human angiosarcoma EC line. They also detected both ACh and VAChT in human ECs.
Using northern blot analysis, Tracey and Peach (65) identified the expression of mRNAs encoding the M 1 , M 2 , and M 3 mAChR subtypes in freshly isolated bovine ECs, while Elhusseiny et al. (66) found consistent expression of M 2 and M 5 mAChRs and occasional expression of M 1 mAChRs in human brain microvessel ECs. M 1 mAChRs have also been detected in the endothelium of human pulmonary veins (67) .
ECs also express several nAChR subunits, including the α3, α5, β2, and β4 subunits in primary cultures of ECs from human aorta (68) and the α2, α3, α4, α5, α7, β2, and β4 subunits in rat microvascular ECs (69) . α7 nAChRs have been shown to mediate EC proliferation, survival, migration, and tube formation in vitro and to mediate angiogenesis in vivo. It also has been suggested that α7 nAChR signaling is related to pathological angiogenesis, playing a significant role in tumor growth and the progression of atherosclerosis (70).
3-8. Miscellaneous 3-8-1. Fibroblasts
Human fibroblasts and myofibroblasts isolated from lung tissues express the M 1 , M 2 , and M 3 mAChR subtypes (71) . ACh-stimulated proliferation of these cells is inhibited by tiotropium, an mAChR antagonist, suggesting that cholinergic signaling mediated by mAChRs could contribute to the remodeling processes seen in chronic airway disease.
3-8-2. Tendon
Prompted by the knowledge that stimulation of AChRs affects processes such as pain sensation, collagen production, angiogenesis, and cell proliferation and outgrowth, like that seen in tendinosis, Danielson et al. (72) investigated the expression of cholinergic components in human tendon cells (tenocytes). They found strong expression of ChAT and VAChT in tenocytes, as well as the mRNAs for M 2 mAChRs and ChAT, suggesting that excessive local production of ACh might be related to the pain sensation and the pathophysiology underlying the development of tendinosis.
3-8-3. Embryonic stem cells
It has been reported that developing tissues express cholinergic markers like AChE, BChE, and AChRs (73, 74) and that their expression is highly regulated developmentally. Paraoanu et al. (75) used RT-PCR, histochemistry, and measurements of enzyme activity to study the expression of cholinergic components in a murine embryonic stem cell line. As expected, they found that embryonic stem cells express ACh, all five mAChR subtypes (M 1 -M 5 ), ChAT, AChE, and BuChE. Inhibition of BuChE caused a reduction in proliferation, suggesting that locally produced ACh functions as an intercellular signal acting via mAChRs to modulate stem cell proliferation.
3-8-4. Skeletal muscle
Tucek (9) showed that some ACh synthesis in dener-vated extensor digitorum longus muscles of the rat is catalyzed by CarAT, but the physiological function of ACh synthesized by CarAT is not known. Later, Hamann et al. (76) found that proliferating myoblasts contained a small amount of ACh-like compound and that this compound was synthesized by BrACh-sensitive ChAT in all myogenic cells. The ACh-like compound was spontaneously released from both myoblasts and myotubes in a partially Ca 2+ -dependent manner. It was therefore suggested that human myogenic cells synthesize and release an ACh-like compound to promote the fusion process that occurs in muscle during growth and regeneration.
Conclusion
Studies have shown that non-neuronal cholinergic systems are expressed in numerous tissues and cells and are involved in the regulation of their function. Moreover, abnormalities of these non-neuronal cholinergic systems appear to be related to the pathology of certain diseases, and the evidence suggests that non-neuronal cholinergic systems are potentially useful therapeutic targets.
